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Abstract
Background: Numerous studies have shown that Epstein-Barr virus (EBV) and cytomegalovirus (CMV) can infect
immunocompetent patients simultaneously with other agents. Nonetheless, multiple infections with other agents
in EBV/CMV-infected children have received little attention. We conducted a retrospective study of children with
suspected infectious mononucleosis. Peripheral blood samples were analyzed by indirect immunofluorescence to
detect EBV, CMV and other respiratory agents including respiratory syncytial virus; adenovirus; influenza virus types
A and B; parainfluenza virus types 1, 2 and 3; Chlamydia pneumoniae and Mycoplasma pneumoniae. A medical
history was collected for each child.
Results: The occurrence of multipathogen infections was 68.9%, 81.3% and 63.6% in the children with primary EBV,
CMV or EBV/CMV, respectively, which was significantly higher than that in the past-infected group or the
uninfected group (p < 0.001). Of the multipathogen-infected patients, the incidence of C. pneumoniae in children
with primary infection was as high as 50%, significantly higher than in the other groups (p < 0.001). In the patients
with multipathogen infection and EBV/CMV primary infection, fever, rash, lymphadenopathy, hepatomegaly,
splenomegaly, atypical lymphocytes and abnormal liver function were more frequent and the length of hospital
stay and duration of fever were longer than in other patients.
Conclusion: Our study suggests that there is a high incidence of multipathogen infections in children admitted
with EBV/CMV primary infection and that the distribution of these pathogens is not random.
Introduction
Epstein-Barr virus (EBV) and Cytomegalovirus (CMV),
members of the herpesvirus family, are common viruses
that cause infectious mononucleosis (IM) characterized
by fever, pharyngitis and lymphadenopathy. EBV/CMV
infects at least 90% of the world’sp o p u l a t i o na n dc a n
persist in a latent form after primary infection. Reactiva-
tion can occur years later, particularly under conditions
of immunosuppression [1,2]. The primary infection may
occur shortly after the disappearance of maternal anti-
bodies during infancy [3]. In childhood, EBV is the most
common cause of IM, but primary CMV infection will
cause up to 7% of cases of mononucleosis syndrome
and will manifest symptoms almost indistinguishable
from those of EBV-induced mononucleosis [4].
It is well known that EBV and CMV are common
opportunistic infection agents in the immunocompro-
mised, including human immunodeficiency virus-infected
individuals, and are a major source of serious viral com-
plications in organ transplant recipients [5]. Children are
also a susceptible population at high risk of CMV/EBV
infection. During growth and development, CMV/EBV
infection can depress the host immune response: this is a
major cause of recurrent childhood microbial infection
[6]. Because CMV and EBV have so much in common,
coinfection with these two viruses occurs occasionally in
children [7-9]. Numerous studies have shown that EBV/
CMV can infect immunocompetent patients simulta-
neously with other agents including respiratory syncytial
virus (RSV), Chlamydia pneumoniae (CP), human her-
pesvirus 6, measles virus and others[7,10-14], and it has
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detected immune deficiency can suffer from mixed infec-
tions with other agents[12,14]. In a previous study, we
found that multipathogen infection is not random but is
related to specific agents. Nonetheless, multiple infec-
tions of EBV/CMV and other agents have received little
attention. The aim of this study was to explore the clini-
cal features and incidence of coinfection of EBV/CMV
and respiratory pathogens in children hospitalized with
suspected IM.
Results
Clinical features
EBV infection
Of the 190 patients, 164 had detectable EBV antibodies.
The age range of this group was from 1-164 months
(mean 46.9 ± 35.7 months) with a male: female ratio of
1.73:1 (102 boys and 62 girls). Forty patients had
primary EBV infection, 48 past infection and 76 were
uninfected. The clinical characteristics of these three
groups are presented in Table 1. There were no differ-
ences between the groups in incidence of fever, rash,
palatal petechiae or splenomegaly, but the mean hospital
stay in the past-infected group was the shortest (7.71 ±
3.07 days). The patients with EBV primary infection had
a higher incidence of lymphadenopathy than the other
two groups (p < 0.001). In the primary-infection and
past-infected groups pharyngitis and hepatomegaly were
more frequent than in uninfected patients (p = 0.02 and
0.013, respectively). There were no differences between
these three groups in their main laboratory results,
except that the percentage of patients with > 10% atypi-
cal lymphocytes was higher in the primary- and past-
infected groups than in the uninfected group and the
frequency of C-reactive protein (CRP) > 10 mg/L was
significantly lower in the primary-infection group.
CMV infection
Of the 190 patients, 165 had the test for CMV-specific
antibodies, including 106 boys and 59 girls (a male:female
ratio of 1.80:1) with ages ranging from 1-164 months
(mean 43.5 ± 35.4 months). Twenty-five patients had pri-
mary CMV infection, 104 were past-infected and 36
uninfected. Compared with the other two groups, the pri-
mary-infection group had a longer hospital stay and more
frequent presentation of palatal petechiae, hepatomegaly
and splenomegaly, atypical lymphocytes > 10% and
abnormal liver function, but fewer rashes. Although the
total numbers of white blood cells (WBC), platelet and
hemoglobin values did not differ among groups, the pri-
mary-infected children had the lowest percentage of neu-
trophils (24.15 ± 15.70%, p =0 . 0 0 1 )a n dt h eh i g h e s t
percentage of lymphocytes (62.03 ± 16.74%, p =0 . 0 0 3 ) .
No parameter differed significantly between the past-
infected and uninfected groups (Table 2).
EBV or CMV infection and clinical features
Patients were classified into three groups. Group A
included 58 patients who had primary infection with
EBV or CMV, group B consisted of 96 patients with
past infection with EBV or CMV and group C consisted
of 36 patients uninfected with EBV or CMV. The clini-
cal features of these groups are shown in Fig. 1. Com-
pared with groups B and C, group A had longer hospital
stays and lymphadenopathy, hepatomegaly, splenome-
galy, atypical lymphocytes > 10% and abnormal liver
function were more frequent. The proportion of patients
with CRP > 10 mg/L was greater in group C than in the
other two groups (p = 0.03). There were no differences
between groups A, B and C in duration of fever, inci-
dence of fever, rash, pharyngitis and palatal petechiae or
elevated erythrocyte sedimentation rate (ESR).
In addition, seven children showed both EBV and
CMV primary infection (Table 3). Of these, six were less
Table 1 The main clinical features in patients grouped by
EBV detection
Clinical features primary
infected
(n = 40)
past infected
(n = 48)
uninfected
(n = 76)
Age 8-164 months 2-163 months 1-140 months
1-12 months 3 (7.50%) 7 (14.6%) 20 (26.3%)
12-36 months 17 (42.5%) 11 (22.9%) 23 (30.3%)
36-72 months 8 (20.0%) 17 (35.4%) 21 (27.6%)
> 72 months 12(30.0%) 13(27.1%) 12(15.8%)
Sex, male/female 20/20 20/18 52/24
Length of stay, days 9.53 ± 3.52* 7.71 ± 3.07** 9.11 ± 4.11*
Duration of fever,
days
6.43 ± 4.21 6.04 ± 4.19 4.99 ± 4.67
Fever 36 (90%) 42 (87.5%) 64 (84.2%)
Rash 8 (20.0%) 9 (18.8%) 13 (17.1%)
Lymphadenopathy 24 (60.0%)* 14 (29.2%)** 29 (38.2%)**
Pharyngitis 39 (97.5%) 45 (93.8%) 75 (98.7%)
Palatal petechiae 9 (22.5%) 13 (27.1%) 16 (21.1%)
Hepatomegaly 8 (20.0%)* 9 (18.8%)* 7 (9.21%)**
Splenomegaly 4 (10.0%) 3 (6.25%) 4 (5.26%)
ALC < 10% 10/27 (37.0%)* 11/26(42.3%)** 11/46 (23.9%)*
Elevated ESR 16/28 (57.1%) 18/31 (58.1%) 19/43 (44.2%)
CRP > 10 mg/L 13/26 (50.0%)* 22/33(66.7%)** 31/48(64.6%)**
ALF 7/22 (31.8%) 5/18 (27.8%) 10/24 (41.7%)
WBC count, 10
9/L 11.94 ± 8.58 10.20 ± 5.67 10.47 ± 5.99
Neutrophils, % 40.48 ± 24.43 49.07 ± 21.81 41.99 ± 26.24
Lymphocytes, % 48.37 ± 23.65 39.86 ± 22.03 45.65 ± 25.58
Monocytes, % 9.98 ± 6.12 9.58 ± 4.61 9.86 ± 6.26
Platelets, 10
9/L 263.61 ± 125.37 286.38 ±
142.72
288.90 ±
130.82
Hemoglobin, g/L 116.53 ± 8.85 117.68 ± 10.83 117.90 ± 10.23
Between * and **, the p value < 0.05. ALC: atypical lymphocytes; ESR:
erythrocyte sedimentation rate; CRP: C-reactive protein; ALF: abnormal liver
function (alanine aminotransferase or aspartate aminotransferase higher than
46 U/L); WBC: white blood cell.
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manifestations of IM–fever, pharyngitis and lymphade-
nopathy. Palatal petechiae, hepatomegaly and splenome-
galy were each seen in four children (57.1%) and none
presented with rashes. The occurrence of liver function
abnormalities was 80% (4/5) and an elevation in the pro-
portion of atypical lymphocytes was observed in five
children (5/6, 83.3%). White blood cell counts ranged
from 7.88 × 10
9/L to 43.8 × 10
9/L. Of the seven chil-
dren, four had detectable specific IgM against one or
more of the other 12 respiratory agents. The results
showed one child positive for one type of IgM and the
other three each positive for two types.
The disease spectrum in children with EBV/CMV infection
The disease spectrum was diverse, especially the spec-
trum of EBV infection (Table 4). The most common
disease caused by EBV primary infection was IM (21/40,
52.5%), followed by respiratory tract infection (12/40,
30.0%), Kawasaki disease (1/40, 2.5%), anaphylactic pur-
pura (1/40, 2.5%), idiopathic thrombocytopenic purpura
(1/40, 2.5%), measles (1/40, 2.5%), asthma (1/40, 2.5%),
juvenile rheumatoid arthritis (1/40, 2.5%) and ulcerative
stomatitis (1/40, 2.5%). Of the diseases caused by CMV
primary infection, the most common was also IM (14/
25, 56.0%), followed by respiratory tract infections (9/25,
36.0%).
Coinfection of EBV/CMV with other pathogens
Besides EBV and CMV, 162 patients had detectable spe-
cific IgM against the other 12 pathogens RSV, Adv, Flu
A and B, PIV 1, 2, and 3, CP, MP, Haemophilus influen-
zae, Klebsiella pneumoniae and Legionella pneumophila.
Of these patients, 60 (37.0%) children were uninfected, a
single agent was identified in 30 (18.5%) children and
two or more agents in 72 (44.4%) children. Fig. 2 shows
the details of coinfection with EBV or CMV and other
pathogens. The general distribution of these 12 patho-
gens was similar in the patients with detectable anti-
EBV, anti-CMV and anti-EBV or anti-CMV. We
detected coinfection of multiple other agents and EBV/
CMV in 68.9% of children, and in 63.6% of children
Table 2 The main clinical features in CMV-detected groups
Clinical features primary infected
(n = 25)
past infected
(n = 104)
uninfected
(n = 36)
Age 1-110 months 2-164 months 4-163 months
1-12 months 7 (28.0%) 22 (21.2%) 12 (30.6%)
12-36 months 8 (32.0%) 36 (34.6%) 11 (36.1%)
36-72 months 6 (24.0%) 25 (24.0%) 6 (16.7%)
> 72 months 4 (16.0%) 21 (20.2%) 6 (16.7%)
Sex, male/female 17/8 65/39 24/12
Length of stay, days 13.04 ± 4.16* 8.26 ± 3.07** 8.28 ± 4.14**
Duration of fever, days 5.36 ± 4.32 4.96 ± 4.38 6.03 ± 5.11
Fever 20 (80.0%) 82 (78.8%) 29 (80.6%)
Rash 1 (4.00%)* 24 (23.1%)** 7 (19.4%)**
Lymphadenopathy 13 (52.0%) 37 (35.6%) 9 (25%)
Pharyngitis 23 (92.0%) 101 (97.1%) 34 (94.4%)
Palatal petechiae 10 (40.0%)* 16 (15.4%)** 2 (5.56%)**
Hepatomegaly 13 (52.0%)* 12 (11.5%)** 2 (5.56%)**
Splenomegaly 8 (32.0%)* 3 (2.88%)** 1 (2.78%)**
ALC > 10% 12/16 (75.0%)* 12/58 (20.7%)** 4/14 (28.6%)**
Elevated ESR 8/14 (57.1%) 35/61 (57.4%) 13/21 (61.9%)
CRP > 10 mg/L 8/15 (53.3%) 33/61 (54.1%) 16/22 (72.7%)
ALF 15/21 (71.4%)* 9/37 (24.3%)** 3/13 (23.1%)**
WBC count, 10
9/L 14.42 ± 8.31 11.07 ± 15.72 9.07 ± 6.14
Neutrophils, % 24.15 ± 15.70* 43.60 ± 23.3** 39.44 ± 25.90**
Lymphocytes, % 62.03 ± 16.74* 44.79 ± 22.39** 48.92 ± 25.57**
Monocytes, % 10.63 ± 5.81 9.89 ± 6.36 9.63 ± 4.90
Platelets, 10
9/L 253.96 ± 96.02 304.72 ± 143.25 305.97 ± 121.85
Hemoglobin, g/L 113.30 ± 9.91 118.59 ± 11.92 118.35 ± 12.26
Between * and **, the p value < 0.05. ALC: atypical lymphocytes; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALF: abnormal liver function
(alanine aminotransferase or aspartate aminotransferase higher than 46 U/L); WBC: white blood cell.
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group with only anti-CMV antibodies detected, the pro-
portion was higher at 81.3%, which differed significantly
from the past-infected and uninfected groups.
The patients were divided into six groups based on
the results of testing for antibodies to EBV or CMV and
the other 12 pathogens (Table 5). We compared the
clinical manifestations of these six groups. The symp-
toms and physical signs seemed to be most severe in
the patients of group A (i.e., the patients with EBV or
CMV primary infection and two or more other patho-
gens). In this group, fever, rash, lymphadenopathy, hepa-
tomegaly, splenomegaly, atypical lymphocytes > 10% and
abnormal liver function were all very frequent. In addi-
tion, the length of hospital stay and the duration of
fever were longer than in groups C, D and F.
Fig. 3 shows that in the primary-infection group, coin-
fection with two or three pathogens was most frequent,
with the percentage first increasing then decreasing
when the number of pathogens was more than two. In
this group, up to seven pathogens were detected in indi-
vidual patients. The incidence of coinfection decreased
with the number of pathogens in past-infected and
uninfected children. In the primary-infection group, the
most frequent combination was coinfection of EBV/
CMV with two other agents, while one episode involved
coinfection with five agents and one episode involved
coinfection with seven agents.
The distribution of the 12 pathogens in the multiply
infected patients is presented in Table 6. Overall, the
most frequent pathogens in the EBV/CMV primary infec-
tion group were Flu A and Flu B, followed by CP. In the
Figure 1 Main clinical features in patients grouped by detection of anti-EBV or anti-CMV antibodies. *Differs from the other two groups,
p < 0.05. LAP: lymphadenopathy; P. petechiae: palatal petechiae; H.megaly: hepatomegaly; S.megaly: splenomegaly; ALC: atypical lymphocytes;
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALF: abnormal liver function (alanine aminotransferase or aspartate aminotransferase
higher than 46 U/L).
Table 3 Clinical features of the seven children with EBV
and CMV primary infection
Clinical features Patients
N°1 N°2 N°3 N°4 N°5 N°6 N°7
Age, months 73 59 16 24 65 13 24
Sex female male female male male male male
Fever + + + + + + +
Lymphadenopathy + + + + + + +
Pharyngitis + + + + + + +
Palatal petechiae - + + + + - -
Rash - - - - - - -
Hepatomegaly - + + - + - +
Splenomegaly - + + + + - -
ALT, U/L / 18 77 70 256 77 /
AST, U/L / 28 84 56 54 78 /
WBC count, 10
9/L 7.88 16.2 27.6 22.0 9.14 43.8 10.5
Lymphocyte, % 29.3 70.7 77.4 47.7 75.3 87.0 43.3
ALC, % 4 / 58 57 37 15 56
Other positive
agents
CP,
MP
/ MP / / Adv,
KP
Adv,
MP
ALC: atypical lymphocytes; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; WBC: white blood cell; CP: Chlamydia pneumoniae; MP:
Mycoplasma pneumoniae;K P :Klebsiella pneumoniae; Adv: adenovirus.
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and MP was most frequent in EBV/CMV-uninfected
children. The incidence of RSV, ADV, MP, Flu A, PIV 1
and PIV 2 did not differ between EBV/CMV-uninfected
children and those with primary or past infection. The
incidence of CP in the primary-infection group was sig-
nificantly higher than in the other groups (p < 0.001).
There was a significantly higher proportion of Flu B
(p = 0.003) in uninfected children than in the other
groups. In the primary-infection and uninfected groups,
the proportion infected with PIV 3 was the same and was
significantly higher than in children with past EBV/CMV
infection (p =0 . 0 1 4 ) .H. influenzae was more frequent in
the past-infected group compared with the primary-
infection group, but did not differ compared with the
uninfected group. The incidence of K. pneumoniae in
past-infected children was significantly higher than that
in uninfected patients or those with primary infection
(p < 0.001).
Discussion
EBV and CMV, members of the herpesvirus family,
establish lifelong latent infection. More than 90% of
adults have acquired these two viruses [2]. Infants from
families of lower socioeconomic levels tend to become
infected somewhat earlier than those from better-situated
families. In developed countries, primary EBV infection
can often be delayed to occur in adolescents and young
adults, while in developing countries the prevalence of
IgG antibodies to VCA of EBV can be up to 80% by the
Table 4 The disease spectrum in EBV or CMV primary infected children
Diagnosis EBV primary infected (n = 40) CMV primary infected (n = 25)
N Percentage (%) N Percentage (%)
IM 21 52.5 14 56.0
Respiratory infection 12 30.0 9 36.0
Kawasaki disease 1 2.5
Anaphylactic purpura 1 2.5
Measles 1 2.5
Ulcerative stomatitis 1 2.5
Asthma 1 2.5
JRA 1 2.5
ITP 1 2.5
Hyperbilirubinemia 1 4.0
Infantile hepatitis 1 4.0
IM: infectious mononucleosis; ITP: idiopathic thrombocytopenic purpura; JRA: juvenile rheumatoid arthritis.
Figure 2 Coinfection of EBV or CMV and other pathogens. Between * and ** the p value < 0.01.
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reported[15]. In this study there were only 63 children
(38.4%) under six years old with EBV primary or past
infection. The reason why this percentage is much lower
than that in previous studies may be that the objects
selected for this study presented with some symptoms of
IM. Some authors have noted that maternal antibodies to
EBV, most of which disappear by four months of age,
may serve to prevent the infection during early infancy
[2]. EBV primary infection can occur in infants 2-3
months after the disappearance of maternal antibody
[16], meaning that EBV primary infection may occur in
infants at six months of age. A study in 2001 in Hong
Kong found that the earliest appearance of EBV primary
Table 5 The differences in the main clinical features of children with multiple infections or a single infection
Clinical features A(n = 31) B(n = 14) C(n = 29) D(n = 54) E(n = 12) F(n = 22)
H. stay, days 10.87 ± 4.11** 10.07 ± 4.23 7.69 ± 3.24* 8.09 ± 3.15* 9.08 ± 3.23 7.73 ± 3.88*
D. of fever, days 7.39 ± 3.93** 5.79 ± 4.89 4.62 ± 4.07* 4.80 ± 4.44* 7.33 ± 5.63 4.32 ± 3.20*
Fever 30 (96.8%)** 11 (78.6%)* 22 (75.9%)* 43 (79.6%)* 11 (78.6%)* 19 (86.4%)*
Rash 7 (22.6%) 0 (0) 7 (24.1%) 9 (16.7%) 1 (8.33%) 5 (22.7%)
Lymphadenopathy 16 (51.6%)** 7 (50.0%)** 9 (31.0%)* 13 (24.1%)* 3 (25.0%)* 9 (40.9%)
Pharyngitis 31 (100%) 13 (92.9%) 28 (96.6%) 52 (96.3%) 11 (91.7%) 22 (100%)
Palatal petechiae 6 (19.4%) 4 (28.6%) 6 (20.7%) 8 (14.8%) 4 (33.3%) 4 (18.2%)
Hepatomegaly 7 (22.6%)* 3 (21.4%)* 3 (10.3%)** 4 (7.41%)** 0 (0) 2 (9.09%)**
Splenomegaly 3 (9.38%) 1 (7.41%) 1 (3.45%) 2 (3.70%) 0 (0) 1 (4.55%)
ALC > 10% 8/10 (80.0%)** 5/10 (50.0%)** 2/10 (20.0%)* 8/32 (25.0%)* 2/7 (28.6%)* 4/12 (33.3%)*
Elevated ESR 14/17 (82.4%)** 7/9 (77.8%)* 11/18 (61.1%)* 15/29 (51.7%)* 5/5 (100%)** 8/13 (61.5%)*
CRP > 10 mg/L 9/17 (52.9%)* 5/10 (50.0%)* 9/18 (50.0%)* 16/32 (50.0%)* 7/7 (100%)** 12/15 (80.0%)**
ALF 9/18 (50.0%)* 3/7 (42.3%)* 0/7 (0) 4/17 (23.5%)** 0/3 (0) 2/3 (66.7%)*
A. EBV/CMV primary infection with multiple pathogens. B. EBV/CMV primary infection with a single or no other pathogen. C. EBV/CMV past infection with
multiple pathogens. D. EBV/CMV past infection with a single or no other pathogen. E. EBV/CMV-uninfected children with multiple pathogens. F. EBV/CMV-
uninfected children with a single or no other pathogen. Between * and **, the p value < 0.05. H. stay: hospital stay; D. of fever: duration of fever; ALC: atypical
lymphocytes; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALF: abnormal liver function (alanine aminotransferase or aspartate aminotransferase
higher than 46 U/L); WBC: white blood cell.
Figure 3 Correlations between the percentage of patients and the number of pathogens in children with multiple infections.
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[2], while in our study the youngest infant with EBV past
infection (positive for both VCA-IgG and EBNA-IgG)
was only two months of age. This should rule out the
possibility of protection from maternal antibodies to
EBV-VCA and EBNA.
The defensive responses to infection with EBV/CMV
can be limited or very broad, which leads to diverse
clinical manifestations of infection. The majority of
patients with primary infections are usually asympto-
matic, except for the acute infectious mononucleosis
that is most common in China in children in the 3-6
years age group [15]. Our results showed that the only
significant differences in patients with EBV primary
infection compared with those having past infection or
no infection were a higher incidence of lymphadenopa-
thy and longer hospital stays. The patients in the CMV
primary-infection group had longer hospital stays and
higher frequency of palatal petechiae, hepatomegaly,
splenomegaly, atypical lymphocytes > 10% and abnormal
liver function, but fewer rashes than the other two
groups. This suggested that the differences in clinical
features among the CMV-infected groups occurred
much earlier than those among the EBV-infected
groups. In addition, in this study seven children showed
both EBV and CMV primary infection. They all pre-
sented with the typical manifestations of IM and with a
high occurrence of hepatomegaly (57.1%), splenomegaly
(57.1%) and liver function abnormalities (80.0%). The
rate of coinfection with other pathogens was as high as
100% (5/5), and the prevalence of multi-pathogen infec-
tion was up to 80% (4/5), which was higher than that of
the children with a single EBV or CMV infection. Some
authors have reported cases of children with both EBV
and CMV infection and noted that the course of disease
in these children was longer, but the last word is not yet
in on whether coinfection with both EBV and CMV can
cause other more serious clinical manifestations[8,9].
T h ed i s e a s es p e c t r u mo fE B V / C M Vp r i m a r yi n f e c t i o n
is very diverse, with the most common manifestation
being IM. In most studies published outside China,
about 50% of children with EBV infection develop IM
[17], and the proportion of IM seen in our study was
similar (52.5%), which is much higher than other studies
in China. In most Chinese studies, the proportion of IM
in the disease spectrum is only about 20%, and the most
common effect is respiratory tract infection (about 40%
compared with 30% in our study)[15]. The disease spec-
trum of EBV infection is more diverse than that of
CMV infection. In addition to IM and respiratory tract
infection, Kawasaki disease, anaphylactic purpura, idio-
pathic thrombocytopenic purpura, measles, asthma,
juvenile rheumatoid arthritis and other complications
have been reported. Other diseases have also been
reported including viral encephalitis, facial paralysis,
myocarditis, lymphoma, hemophagocytic syndrome and
systemic lupus erythematosus[15]. The complexity of
the manifestations and the variety of the disease spec-
trum of EBV/CMV primary infection suggest that our
pediatricians should make the diagnosis based on a
comprehensive analysis.
T h en o t a b l ef i n d i n gi no u rs t u d yw a st h ep r e s e n c eo f
coinfection of multiple other agents with EBV/CMV in
more than 60% of the children. In the groups with
detectable CMV antibodies without EBV, this propor-
tion was as high as 81.3%. The most frequent combina-
tion was coinfection with two agents. Research on
multiple infections accompanying EBV/CMV infection is
relatively rare. The prevalence of mixed infection in pre-
vious studies is lower than 10% in young children with
IM, with the most frequent combination being coinfec-
tion with two other pathogens [12]. In contrast, we
found a much higher incidence of coinfection with more
than two agents.
The differences in the incidence of coinfection may be
due to the different types of etiological agents involved
or to the different diagnostic methods applied [18,19].
All of the 12 respiratory pathogens detected in our
study are active in cold and dry environments. It is pos-
sible that these agents would be associated with EBV/
CMV because they circulate most frequently at the
same time of year [20]. The use of the IIF method to
detect antibodies to respiratory pathogens may be
another cause of the higher rate of coinfection in our
study. IIF is only a qualitative method to detect antibo-
dies, and the existence of IgM antibodies cannot guaran-
tee that the child was infected with multiple pathogens
Table 6 The distribution of the other 12 pathogens in
multiply infected children
primary infected past infected uninfected
RSV 9/31 (29.0) 6/28 (21.4) 2/12 (16.7)
ADV 11/31 (35.5) 11/28 (39.3) 3/12 (25.0)
CP 16/31 (51.6)** 7/28 (25.0)* 3/12 (25.0)*
MP 15/31 (48.4) 12/28 (42.9) 4/12 (33.3)
Flu A 12/20 (60.0) 13/18 (72.2) 6/10 (60.0)
Flu B 12/20 (60.0)* 11/18 (61.1)* 8/10 (80.0)**
PIV 1 2/20 (10.0) 2/18 (7.14) 0/10 (0)
PIV 2 1/20 (5.00) 1/18 (3.57) 0/10 (0)
PIV 3 4/20 (20.0)* 2/18 (7.14) ** 2/10 (20.0)*
H. influenzae 1/20 (5.00)* 3/18 (16.7)** 1/10 (10.0)
K. pneumoniae 4/20 (20.0)* 8/18 (44.4)** 2/10 (20.0)*
L. pneumophila 0/20 (0) 0/18 (0) 1/10 (10.0)
Between * and **, the p value < 0.05. RSV: respiratory syncytial virus; Adv:
adenovirus; Flu: influenza virus; PIV: parainfluenza virus; CP: Chlamydia
pneumoniae; MP: Mycoplasma pneumoniae; H. influenzae: Haemophilus
influenzae; K. pneumoniae: Klebsiella pneumoniae; L. pneumophila: Legionella
pneumophila.
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be detected in more than 70% of children with an acute
respiratory tract infection within one week of onset of
infection, after which the IgM level gradually declines
and becomes undetectable three months after the onset
of infection. Thus, the IIF method to detect antibodies
may merely indicate that a child has been infected with
a respiratory pathogen between one week and three
months before the sample was obtained [14].
In the patients with multipathogen infections, EBV/
CMV may be a primary, co-primary, or secondary
pathogen. It may be reactivated in the course of infec-
tion with another agent or, possibly, it may precipitate
infection with some other organism by suppressing
immune function. We prefer the latter hypothesis. Tran-
sient immunosuppression secondary to EBV/CMV infec-
tion has been well described. During the early phase of
acute EBV-related IM, dramatic antigen-driven clonal
expansions of CD8 T lymphocytes with an abnormally
low CD4+/CD8+ ratio were detected [21-23]. Further-
more, B-cell function was impaired and the production
of antibody against other pathogens was inhibited
[24,25], but these abnormalities disappeared during the
convalescent phase. This demonstrates that infection
with EBV can affect both cell-mediated and humoral
immunity, and causes a broad-based transient immuno-
suppression. This immunosuppression may be severe
enough to cause secondary infections in some EBV-
infected individuals, as illustrated by the report of severe
measles and severe RSV pneumonia in patients infected
with EBV [10,13,26]. However, whether it is the EBV/
CMV infection that causes a mixed infection, or
whether the EBV/CMV infection coexists with these dis-
eases is worthy of further exploration.
In this study, the symptoms and physical signs seemed
to be most severe in the patients with EBV/CMV pri-
mary infection and multiple pathogens. Although there
are no similar reports, patients coinfected with EBV/
CMV and a single other pathogen such as CP or RSV
were reported to suffer more severe symptoms [10,11].
In the multiply infected patients, the distribution of the
12 additional pathogens is not random (Table 6). Coin-
fection with certain pathogens occurs more frequently
than expected in the patients with EBV/CMV primary
i n f e c t i o n :C Pa n dP I V3w e r em o r ef r e q u e n t l ys e e na n d
in contrast, all three bacteria were rarer. There have
been no previous reports of similar findings.
In conclusion, we found frequent multipathogen infec-
tions in children admitted with EBV/CMV infection,
and the distribution of these pathogens was not random.
Despite this, because most of the children with coinfec-
tion of EBV/CMV and multiple pathogens are severely
affected, the diagnosis is very important to make.
Further studies are needed toc l a r i f yt h ep a t h o g e n e s i s
and interactions involved in coinfection by different
pathogens.
Study Design
Case selection
One hundred and ninety patients, including 120 boys
and 70 girls with ages ranging from 1-164 months
(mean 43.5 ± 35.4 months), were enrolled for the retro-
spective study. All were admitted to Zhongnan Hospital
of Wuhan University, China, between August 2008 and
September 2009 with suspected IM because they pre-
sented with either (1) at least three of the EBV-related
symptoms of fever, rash, lymphadenopathy, pharyngitis,
palatal petechiae, hepatomegaly, or splenomegaly, or (2)
fever of duration longer than seven days. In addition, all
EBV-associated malignant diseases such as malignant
lymphoma and chronic active EBV infection were
excluded.
Case definition
EBV-infected patients P r i m a r yi n f e c t i o n :p r e s e n c eo f
IgM to viral capsid antigen (VCA) is conventionally
used for diagnosing acute EBV infection. However,
VCA-IgM is usually transient and quickly disappears,
and the test may not be sufficiently sensitive [27-30].
Therefore, in our study, we used an alternative approach
to define primary EBV infection as detection of either
positive IgG to the early antigen (EA) or low-affinity
anti-VCA-IgG or both.
Past infection: positive for IgG to VCA and IgG
to Epstein-Barr nuclear antigen (EBNA), or detection
of high-affinity anti-VCA-IgG without VCA-IgM and
EA-IgG.
Uninfected: no antibodies to EBV detected.
CMV-infected patients Primary infection: positive for
CMV-IgM.
Past infection: detection of CMV-IgG without
CMV-IgM.
Uninfected: no antibodies to CMV detected [31].
Procedures
In this study, a peripheral blood sample was obtained
from all children within the first 24 h of admission to
the pediatric department. Specific antibodies to EBV
and CMV (IgM and IgG to VCA, IgG to EA and EBNA
of EBV, IgM and IgG to CMV) were detected by indir-
ect immunofluorescence (IIF). Ninety-three children had
an additional test for the affinity of IgG against VCA of
EBV (EUROIMMUN, Lübeck, Germany). Moreover,
specific antibodies (IgM, IgG) to another 12 respiratory
pathogens (respiratory syncytial virus (RSV), adenovirus
(Adv), influenza virus (Flu) types A and B, parainfluenza
v i r u s( P I V )t y p e s1 ,2 ,a n d3 ,Chlamydia pneumoniae
(CP) and Mycoplasma pneumoniae (MP), Haemophilus
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Page 8 of 10influenzae, Klebsiella pneumoniae and Legionella pneu-
mophila) were detected using a commercial indirect
immunofluorescence (IIF) kit (EUROIMMUN, Lübeck,
Germany) following the manufacturer’s instructions.
For each patient, the medical history, age of onset,
forewarning signs, symptoms, complications and labora-
tory data at diagnosis were collected and analyzed.
Statistical analysis
General data are presented as the percentage or mean ±
standard deviation (SD). All statistical analyses were per-
formed using SPSS software (version 13; Chicago, IL,
USA). The chi-square test was used to compare
between-group differences in percentages. The differ-
ences among the mean values of white blood cell
counts, hemoglobin and platelets were analyzed using a
one-way ANOVA. p < 0.05 was considered significant.
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